IPO Update: Returns Run Red For Most Biopharma Firms That Went Public In The US Last Year

Nearly two-thirds of the 67 drug developers that launched an IPO in 2018 were trading below their offering price at the end of the year, bringing the average return to -7.5%. Even so, biopharma companies continue to line up for a US stock market debut.